MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurheartj/ehw256

Медицинская библиотека · European heart journal · 2016

Beneficial effects of long-acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation: The NOVEL study.

Tsuburaya Ryuji, Takahashi Jun, Nakamura Akihiro, Nozaki Eiji, Sugi Masafumi, Yamamoto Yoshito, Hiramoto Tetsuya, Horiguchi Satoru, Inoue Kanichi, Goto Toshikazu, Kato Atsushi, Shinozaki Tsuyoshi, Ishida Eiko, Miyata Satoshi, Yasuda Satoshi, Shimokawa Hiroaki, NOVEL Investigators

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

AIMS: It is widely known that drug-eluting stents (DES) induce coronary vasomotion abnormalities. We have previously demonstrated that chronic treatment with long-acting nifedipine suppresses coronary hyperconstricting responses induced by the first-generation DES (e.g. sirolimus- and pacritaxel-eluting stents) through inhibition of vascular inflammation in pigs. To examine whether this is also the case with the second-generation DES (everolimus-eluting stents, EES) in humans, the most widely used DES in the world, we conducted a prospective, randomized, multicentre trial, termed as the NOVEL Study.

METHODS AND

RESULTS

We evaluated 100 patients with stable angina pectoris who underwent scheduled implantation of EES in the left coronary arteries. They were randomly assigned to receive either conventional treatments alone or additionally long-acting nifedipine (10-60 mg/day) (n = 50 each). After 8-10 months, 37 patients in the control and 38 in the nifedipine group were examined for coronary vasoreactivity to intracoronary acetylcholine (ACh) by quantitative coronary angiography after 48-h withdrawal of nifedipine. Coronary vasoconstricting responses to ACh were significantly enhanced at the distal edge of EES compared with non-stented vessel (P = 0.0001) and were significantly suppressed in the nifedipine group compared with the control group (P = 0.0044). Furthermore, the inflammatory profiles were also improved only in the nifedipine group, which evaluated by serum levels of high-sensitivity CRP (P = 0.0001) and adiponectin (P = 0.0039).

CONCLUSIONS

These results indicate that DES-induced coronary vasomotion abnormalities still remain an important clinical issue even with the second-generation DES, for which long-acting nifedipine exerts beneficial effects associated with its anti-inflammatory effects.

TRIAL REGISTRATION: This study is registered at the UMIN Clinical Trial Registry (UMIN-CTR; ID=UMIN000015147).

Для цитирования: Tsuburaya Ryuji, Takahashi Jun, Nakamura Akihiro, Nozaki Eiji, Sugi Masafumi, Yamamoto Yoshito, Hiramoto Tetsuya, Horiguchi Satoru, Inoue Kanichi, Goto Toshikazu, Kato Atsushi, Shinozaki Tsuyoshi, Ishida Eiko, Miyata Satoshi, Yasuda Satoshi, Shimokawa Hiroaki, NOVEL Investigators. Beneficial effects of long-acting nifedipine on coronary vasomotion abnormalities after drug-eluting stent implantation: The NOVEL study.. European heart journal. 2016. DOI: 10.1093/eurheartj/ehw256.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.